All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Shares in Clavis Pharma ASA soared on the Oslo Bors Tuesday, on news that it licensed its Phase II pancreatic cancer drug CP-4126 to Clovis Oncology Inc., for an up-front payment of $15 million, plus a potential $365 million in development, regulatory and sales-related milestones. (BioWorld Today)